I-BET-762: A Selective BET Bromodomain Inhibitor for Inflammation and Cancer Research

Executive Summary: I-BET-762 (SKU B1498) is a highly potent and selective BET bromodomain inhibitor with nanomolar affinity for the acetyl-lysine binding pocket of BET proteins (IC₅₀: 32.5–42.5 nM; K_d: 50.5–61.3 nM) [APExBIO]. This compound competitively displaces acetyl-lysine and does not significantly affect other bromodomain-containing proteins [Fan et al., 2024]. I-BET-762 downregulates LPS-induced cytokine and chemokine expression, yielding measurable anti-inflammatory effects in vivo. It also synergizes with ferroptosis inducers to promote cancer cell death through ROS and FSP1 modulation. The compound is widely used in epigenetics, transcriptional regulation, inflammation, and cancer biology workflows due to its reproducibility and selectivity.

Biological Rationale

Bromodomain and extra-terminal domain (BET) proteins are central regulators of gene expression via recognition of acetyl-lysine marks on histones. The BET family includes BRD2, BRD3, BRD4, and BRDT, which mediate transcriptional activation of genes involved in inflammation, cancer, and cell fate. Dysregulation of BET pathways is implicated in aberrant cytokine production, tumorigenesis, and resistance to cell death. Inhibition of BET proteins modulates these pathways, offering a targeted strategy for both inflammation and oncology research [Fan et al., 2024]. Selective BET inhibitors like I-BET-762 are designed to block acetyl-lysine recognition, thereby altering chromatin accessibility and gene transcription in a controlled, reproducible manner.

Mechanism of Action of I-BET-762

I-BET-762 binds the acetyl-lysine (AcK) binding pocket of BET proteins with high affinity (K_d: 50.5–61.3 nM), competing with acetylated histone substrates. The molecule demonstrates a unique 2:1 binding stoichiometry with BET bromodomains, which enhances selectivity and affinity [APExBIO]. This interaction disrupts the recruitment of BET proteins to chromatin, preventing activation of LPS-inducible and oncogenic genes. Functionally, I-BET-762 suppresses the expression of inflammatory cytokines and chemokines in LPS-stimulated cells, and downregulates FSP1—a key ferroptosis suppressor—thereby sensitizing cancer cells to ferroptotic death [Fan et al., 2024]. The selectivity profile of I-BET-762 ensures minimal off-target activity against non-BET bromodomains.

Evidence & Benchmarks

• I-BET-762 exhibits potent inhibition of BET proteins with IC₅₀ values between 32.5 and 42.5 nM in cell-free assays (APExBIO, product page).
• High-affinity binding (K_d: 50.5–61.3 nM) was determined using biophysical and structural assays (product documentation).
• I-BET-762 selectively inhibits BET proteins, showing no significant interaction with other bromodomain-containing proteins (Fan et al., 2024, DOI).
• In mouse models, I-BET-762 downregulates LPS-induced cytokine production and ameliorates inflammatory disease phenotypes (Fan et al., 2024, DOI).
• BRD4 inhibition by I-BET-762 or genetic knockdown enhances erastin-induced ferroptosis in HEK293T, HeLa, HepG2, RKO, and PC3 cells by increasing ROS and decreasing FSP1 expression (Fan et al., 2024, DOI).
• In HEK293T cells, I-BET-762 treatment increases FTH1, Nrf2, and GPX4, while reducing VDAC2, VDAC3, and FSP1; in HeLa cells, it reduces FTH1, VDAC2/3, Nrf2, GPX4, and FSP1 (Fan et al., 2024, DOI).

For additional scenario-driven guidance on experimental optimization, see I-BET-762 (SKU B1498): Optimizing BET Inhibition for Reliable Ferroptosis Assays, which this article updates by integrating new mechanistic insights on FSP1 and ROS regulation.

Researchers seeking an analysis of translational strategies can refer to I-BET-762 and the Next Frontier in BET Inhibition; this current dossier provides a more granular breakdown of evidence tiers and selectivity claims.

For a comprehensive workflow perspective, I-BET-762: A Selective BET Inhibitor for Epigenetic and Inflammation Research covers integration steps, while this article clarifies recent advances in ferroptosis benchmarks and molecular selectivity.

Applications, Limits & Misconceptions

I-BET-762 (APExBIO, product page) is validated for research in the following domains:

• Epigenetic regulation and chromatin remodeling studies.
• Suppression of LPS-inducible gene expression in inflammation models.
• Induction of ferroptosis in combination with inducers (e.g., erastin) in preclinical cancer models.
• Selective modulation of BET protein signaling pathways in cell-based and in vivo assays.
• Investigation of transcriptional regulation mechanisms in acute inflammatory responses and cancer progression.

Common Pitfalls or Misconceptions

• I-BET-762 is not a pan-bromodomain inhibitor; it is selective for BET family members and does not block all bromodomain-containing proteins.
• The compound is insoluble in water; DMSO or ethanol (with sonication) is required for solution preparation (APExBIO).
• Not suitable for long-term solution storage; stock solutions should be used promptly for data reliability.
• Anti-inflammatory effects are context-dependent and must be validated in the specific cell type or animal model used.
• Ferroptosis induction by I-BET-762 is synergistic with inducers like erastin, but not sufficient alone to trigger cell death in all contexts.

Workflow Integration & Parameters

Formulation and Storage: I-BET-762 is a solid with a molecular weight of 423.9 g/mol and formula C₂₂H₂₂ClN₅O₂. Dissolve at ≥21.19 mg/mL in DMSO or ≥13.93 mg/mL in ethanol (sonication recommended). Store powder at -20°C; use solutions only for short-term experiments (APExBIO).

Experimental Conditions:

• Typical in vitro concentrations: 1–2 μM for cell viability, gene expression, or ferroptosis assays.
• In vivo studies require dosing optimization based on animal model and endpoint.
• Controls: Include DMSO vehicle and, where applicable, BET-inactive analogs.
• Readouts: RT-qPCR for gene expression, ELISA for cytokines, CCK-8 for viability, and ROS/FSP1 quantification for ferroptosis studies (Fan et al., 2024).

For protocol optimization and troubleshooting, see I-BET-762: A Selective BET Bromodomain Inhibitor for Advanced Disease Models, which this article extends with updated evidence and storage guidance.

Conclusion & Outlook

I-BET-762 from APExBIO is a validated, high-affinity BET inhibitor for research on epigenetic regulation, inflammation, and ferroptosis. Its selectivity and robust activity profile make it a benchmark tool compound for dissecting BET protein signaling in preclinical models. With continued research into the interplay between BET inhibition and ferroptosis, I-BET-762 is poised to support next-generation studies in transcriptional regulation, cancer, and inflammatory disease therapeutics. For detailed product specifications and ordering, refer to the I-BET-762 product page.